The Claim
The claim is that routine use of high-cycle reverse-transcription polymerase chain reaction (RT-PCR) testing generated large numbers of false-positive COVID-19 cases and thereby materially inflated official case counts.
Three different questions are often compressed into this claim:
- can PCR produce an analytically false-positive result?
- can PCR detect viral RNA when a person is no longer infectious?
- did either phenomenon occur often enough to materially inflate official population case counts?
They are not interchangeable.
Where It Comes From
During the pandemic, laboratories often ran SARS-CoV-2 RT-PCR assays through many amplification cycles.
A weak positive near an assay’s detection limit can correspond to a high cycle-threshold value.
Studies also showed that samples with high Ct values were much less likely to yield culturable virus.
These observations were frequently summarized online as “PCR at 35 or 40 cycles produces fake cases.”
That wording mixes analytical specificity with infectiousness.
Why It Sounds Convincing
PCR is extraordinarily sensitive.
When disease prevalence is very low, even a highly specific test can produce a meaningful fraction of false positives among all positive results.
Contamination and laboratory errors can also happen.
And a person can remain PCR-positive after the period in which viable virus can readily be cultured.
All of those statements are true.
The open question is whether they add up to the much stronger claim that official case counts were materially inflated by false positives.
The Short Answer
False-positive PCR results occurred, and low-prevalence mass screening could produce poor positive predictive value. But the evidence reviewed so far does not show that false positives materially inflated official COVID-19 case counts overall.
High Ct is relevant to infectiousness and viral burden. It is not itself proof that a test result is false.
A PCR result can correctly detect SARS-CoV-2 RNA in someone who is no longer contagious.
That distinction is central.
How It Would Have to Work
For high-cycle PCR testing to have substantially inflated reported cases at population scale, the following conditions would need to hold:
- large numbers of people without SARS-CoV-2 RNA would need to test positive because of analytical error, contamination or nonspecific amplification;
- those results would need to enter official case statistics without adequate confirmation;
- the false-positive fraction would need to be large enough across substantial periods to change the interpretation of epidemic magnitude.
A high Ct threshold alone does not demonstrate any of those three steps.
What Actually Happens
PCR amplifies a target sequence
RT-PCR converts viral RNA into complementary DNA and amplifies selected genomic targets.
The cycle threshold records when fluorescence crosses an assay-defined threshold.
Ct is assay-dependent. A Ct of 35 on one platform is not automatically equivalent to 35 on another.
High Ct often means less recoverable infectious virus
Across viral-culture studies, higher Ct values and longer time from symptom onset are associated with lower probability of culturing viable virus.
That makes Ct potentially informative about infectiousness.
But viral culture and molecular detection ask different questions.
Analytical false positives are real
False positives can arise through contamination, specimen handling, plate errors, nonspecific reactions or rare technical failures.
A quality-control study of 24,717 tests identified 20 erroneous positives among 288 initial positives in the reviewed asymptomatic testing group.
In low-prevalence settings the problem can become proportionally larger among positives. A Cambridge study found that 23 of 52 first-time positive detections failed confirmation during a very low-prevalence period.
Pre-test probability changes positive predictive value
Even with high specificity, a positive result becomes less trustworthy when the tested population has extremely low prevalence.
That is basic conditional probability, not a unique flaw of PCR.
Confirmatory testing can reduce this problem.
What the Evidence Shows
PCR assays for SARS-CoV-2 were generally highly specific.
They were not perfect.
Low-prevalence screening studies demonstrate that an initially positive result can have substantially lower positive predictive value than headline assay specificity suggests.
The Cambridge low-prevalence study makes the size and the limit of that problem concrete. Across 19,597 samples, 107 contained a SARS-CoV-2 RNA detection; 52 were first detections in previously negative patients. Of those 52 initially positive samples, 29 were confirmed on additional testing and 23 were not. Non-confirmation is a warning about possible false positives in that particular testing setting, not evidence that each of the 23 was definitively false or that 44% of all pandemic cases were false. Those 52 first detections were only 0.27% of the laboratory’s total tests.
That is strong evidence for a real diagnostic problem under certain conditions.
It still does not establish that the aggregate pandemic case curve was largely or materially produced by false positives.
The more common conceptual error is treating a true RNA detection in a low-infectiousness or recovered person as if it were analytically false.
That may still raise legitimate questions about isolation policy or how a “case” should be interpreted.
It is not the same claim.
The Strongest Evidence for the Claim
The strongest evidence includes:
- documented laboratory false positives;
- large drops in positive predictive value during very low prevalence;
- high-Ct results that frequently fail to reproduce on another assay;
- persistent RNA detection after infectious virus becomes difficult to culture.
These observations show why universal interpretation of every PCR-positive result as equivalent epidemiological evidence is too simplistic.
The Strongest Evidence Against It
Real-world molecular assays generally had high analytical specificity.
Where false positives were systematically investigated, they existed but represented a small fraction of all tests.
A large fraction of false positives among positives in a very low-prevalence group is not the same as a large fraction of all reported cases across the pandemic.
No population reconstruction identified in this research pass demonstrates that analytically false-positive PCR results constituted a material share of cumulative official case counts.
Common Viral Arguments
“A Ct above 35 means the test is false.”
No. It usually indicates a low amount of target RNA under that assay’s conditions. Whether the result is reproducible and whether the person is infectious are separate questions.
“If you cannot culture virus, the PCR result is false.”
No. Viral culture measures recoverable infectious virus. PCR measures target nucleic acid.
“A test with 99% specificity creates millions of false cases.”
Not without knowing how many tests were performed, actual assay specificity, disease prevalence, repeat testing and how official cases were counted.
“PCR was never meant to diagnose disease.”
PCR is a laboratory technique. Its diagnostic usefulness depends on assay validation, target, sampling, clinical context and the definition of the condition being diagnosed.
The Reasoning Error
The key error is a category error: detection of RNA, infectiousness and clinical disease are treated as though they were the same variable.
Base-rate neglect also matters. Positive predictive value changes with prevalence even if assay sensitivity and specificity remain constant.
What Would Change Our Conclusion?
A credible reconstruction showing that analytically false-positive tests made up a substantial fraction of official reported cases over meaningful periods would change the conclusion.
That would require assay-specific data, prevalence, repeat-testing results, Ct distributions and case-definition rules.
Conversely, representative confirmation studies across testing programs showing consistently negligible false-positive contribution would strengthen a contradicted verdict.
Evidence Status
Status: Unsupported
Evidence quality: Moderate
False positives and high-Ct interpretive problems were real. Current evidence does not establish the stronger population claim that they materially inflated overall official case counts.
Evidence & Sources
Central sources:
- Skittrall et al., Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in a low-prevalence setting, Clinical Microbiology and Infection, 2021.
- Layfield et al., RT-PCR false-positive quality-control study, 2021.
- Serial cycle threshold to assess the infectious potential of SARS-CoV-2: A systematic review, 2026.
- studies of RT-PCR Ct, viral culture and pre-test probability.
Corrections & Updates
October 10, 2026 — evidence clarification. Quantified the low-prevalence PCR confirmation study (52 first positives, 29 confirmed, 23 not), without treating nonconfirmation or high Ct as national analytical false-positive prevalence. Unsupported / Moderate unchanged.
Last Reviewed
October 10, 2026.